newsfilter
← Latest News
GlobeNewswire·

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021

Validated ability to Drug the Genome™ to address both rare and common diseases without the limitations of early precision genetic medicine technologies; the Company's delivery shuttle enables pharmacology across programs in multiple tissues, including